Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...

Mereo BioPharma Group plc has provided updates on its key clinical programs, including the ongoing Phase 3 Orbit study for setrusumab, which is being developed for osteogenesis imperfecta (OI ...

Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

Shares of Mereo BioPharma (NASDAQ:MREO) rose 7% Friday after Jefferies initiated coverage of the stock with a buy rating, citing the company’s drug candidates setrusumab and alvelestat.

Ultragenyx’s recent meeting focused on setrusumab and the ongoing Phase 3 ORBIT trial. The analyst noted that the company remains confident in the trial’s success, with a second interim ...

“Based on the highly promising data from completed studies of setrusumab in OI, including the Phase 2 portion of the Orbit Study, we remain confident in the potential of setrusumab to become the ...

The company also provided key program updates including that the UX143 (setrusumab) Phase 3 Orbit study is progressing with the second interim analysis in mid-2025. “In 2024 we grew our business ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung ...

Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on European Orphan Designation Application; European Commission expected to issue final ...

LONDON, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an ...